Interleukin-17 and innate immunity in infections and chronic inflammation

Natasa Isailovic, Kenji Daigo, Alberto Mantovani, Carlo Selmi

Research output: Contribution to journalArticle

174 Citations (Scopus)

Abstract

Interleukin 17 (IL-17) includes several cytokines among which IL-17A is considered as one of the major pro-inflammatory cytokine being central to the innate and adaptive immune responses. IL-17 is produced by unconventional T cells, members of innate lymphoid cells (ILCs), mast cells, as well as typical innate immune cells, such as neutrophils and macrophages located in the epithelial barriers and characterised by a rapid response to infectious agents by recruiting neutrophils as first line of defence and inducing the production of antimicrobial peptides. Th17 responses appear pivotal in chronic and acute infections by bacteria, parasites, and fungi, as well as in autoimmune and chronic inflammatory diseases, including rheumatoid arthritis, psoriasis, and psoriatic arthritis. The data discussed in this review cumulatively indicate that innate-derived IL-17 constitutes a major element in the altered immune response against self antigens or the perpetuation of inflammation, particularly at mucosal sites. New drugs targeting the IL17 pathway include brodalumab, ixekizumab, and secukinumab and their use in psoriatic disease is expected to dramatically impact our approach to this systemic condition.

Original languageEnglish (US)
Pages (from-to)1-11
Number of pages11
JournalJournal of Autoimmunity
Volume60
DOIs
StatePublished - Jun 1 2015
Externally publishedYes

Fingerprint

Interleukin-17
Innate Immunity
Inflammation
LY2439821
Infection
Neutrophils
Cytokines
Psoriatic Arthritis
Parasitic Diseases
Mycoses
Autoantigens
Adaptive Immunity
Drug Delivery Systems
Psoriasis
Mast Cells
Rheumatoid Arthritis
Chronic Disease
Macrophages
Lymphocytes
Bacteria

Keywords

  • Brodalumab
  • Infection
  • Ixekizumab
  • Psoriasis
  • Psoriatic arthritis
  • Secukinumab

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Interleukin-17 and innate immunity in infections and chronic inflammation. / Isailovic, Natasa; Daigo, Kenji; Mantovani, Alberto; Selmi, Carlo.

In: Journal of Autoimmunity, Vol. 60, 01.06.2015, p. 1-11.

Research output: Contribution to journalArticle

Isailovic, Natasa ; Daigo, Kenji ; Mantovani, Alberto ; Selmi, Carlo. / Interleukin-17 and innate immunity in infections and chronic inflammation. In: Journal of Autoimmunity. 2015 ; Vol. 60. pp. 1-11.
@article{bbae597137e24d46a7db6a817f3cb70e,
title = "Interleukin-17 and innate immunity in infections and chronic inflammation",
abstract = "Interleukin 17 (IL-17) includes several cytokines among which IL-17A is considered as one of the major pro-inflammatory cytokine being central to the innate and adaptive immune responses. IL-17 is produced by unconventional T cells, members of innate lymphoid cells (ILCs), mast cells, as well as typical innate immune cells, such as neutrophils and macrophages located in the epithelial barriers and characterised by a rapid response to infectious agents by recruiting neutrophils as first line of defence and inducing the production of antimicrobial peptides. Th17 responses appear pivotal in chronic and acute infections by bacteria, parasites, and fungi, as well as in autoimmune and chronic inflammatory diseases, including rheumatoid arthritis, psoriasis, and psoriatic arthritis. The data discussed in this review cumulatively indicate that innate-derived IL-17 constitutes a major element in the altered immune response against self antigens or the perpetuation of inflammation, particularly at mucosal sites. New drugs targeting the IL17 pathway include brodalumab, ixekizumab, and secukinumab and their use in psoriatic disease is expected to dramatically impact our approach to this systemic condition.",
keywords = "Brodalumab, Infection, Ixekizumab, Psoriasis, Psoriatic arthritis, Secukinumab",
author = "Natasa Isailovic and Kenji Daigo and Alberto Mantovani and Carlo Selmi",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.jaut.2015.04.006",
language = "English (US)",
volume = "60",
pages = "1--11",
journal = "Journal of Autoimmunity",
issn = "0896-8411",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Interleukin-17 and innate immunity in infections and chronic inflammation

AU - Isailovic, Natasa

AU - Daigo, Kenji

AU - Mantovani, Alberto

AU - Selmi, Carlo

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Interleukin 17 (IL-17) includes several cytokines among which IL-17A is considered as one of the major pro-inflammatory cytokine being central to the innate and adaptive immune responses. IL-17 is produced by unconventional T cells, members of innate lymphoid cells (ILCs), mast cells, as well as typical innate immune cells, such as neutrophils and macrophages located in the epithelial barriers and characterised by a rapid response to infectious agents by recruiting neutrophils as first line of defence and inducing the production of antimicrobial peptides. Th17 responses appear pivotal in chronic and acute infections by bacteria, parasites, and fungi, as well as in autoimmune and chronic inflammatory diseases, including rheumatoid arthritis, psoriasis, and psoriatic arthritis. The data discussed in this review cumulatively indicate that innate-derived IL-17 constitutes a major element in the altered immune response against self antigens or the perpetuation of inflammation, particularly at mucosal sites. New drugs targeting the IL17 pathway include brodalumab, ixekizumab, and secukinumab and their use in psoriatic disease is expected to dramatically impact our approach to this systemic condition.

AB - Interleukin 17 (IL-17) includes several cytokines among which IL-17A is considered as one of the major pro-inflammatory cytokine being central to the innate and adaptive immune responses. IL-17 is produced by unconventional T cells, members of innate lymphoid cells (ILCs), mast cells, as well as typical innate immune cells, such as neutrophils and macrophages located in the epithelial barriers and characterised by a rapid response to infectious agents by recruiting neutrophils as first line of defence and inducing the production of antimicrobial peptides. Th17 responses appear pivotal in chronic and acute infections by bacteria, parasites, and fungi, as well as in autoimmune and chronic inflammatory diseases, including rheumatoid arthritis, psoriasis, and psoriatic arthritis. The data discussed in this review cumulatively indicate that innate-derived IL-17 constitutes a major element in the altered immune response against self antigens or the perpetuation of inflammation, particularly at mucosal sites. New drugs targeting the IL17 pathway include brodalumab, ixekizumab, and secukinumab and their use in psoriatic disease is expected to dramatically impact our approach to this systemic condition.

KW - Brodalumab

KW - Infection

KW - Ixekizumab

KW - Psoriasis

KW - Psoriatic arthritis

KW - Secukinumab

UR - http://www.scopus.com/inward/record.url?scp=84931006653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931006653&partnerID=8YFLogxK

U2 - 10.1016/j.jaut.2015.04.006

DO - 10.1016/j.jaut.2015.04.006

M3 - Article

C2 - 25998834

AN - SCOPUS:84931006653

VL - 60

SP - 1

EP - 11

JO - Journal of Autoimmunity

JF - Journal of Autoimmunity

SN - 0896-8411

ER -